Finerenone Placebo

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

8 competitors in Diabetic Kidney Disease

#DrugCompanyPhaseTrials

1

Kerendia

Bayer

Approved

22

Jardiance

Boehringer Ingelheim

Approved

23

Mazdutide

Eli Lilly

Phase 3

14

Angiotensin Receptor Blocker

NNational University of Ireland, Galway, Ireland

Phase 3

15

Finerenone Placebo

Bayer

Phase 3

16

R3R01

RRiver 3 Renal Corp.

Phase 2

17

AP303 150μg

AAlebund Pharmaceuticals

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diabetic Kidney Disease1 trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Acute Heart Failure1 trial

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

Recruiting·JJuntendo University·Approved·NCT07397650·550 enrolled

Type 2 Diabetes Mellitus1 trial

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

Completed·Bayer·Phase 2·NCT05254002·1,664 enrolled

Details

Drug Info

Related News